Buying vs. R&D: Is it Cheaper to Acquire Existing Biotechs or Invest in Your Own R&D?
<p>The quest for the next blockbuster drug is a high-stakes game in the pharma industry. Two main paths lead to this coveted prize: internal R&D, the detailed but potentially rewarding journey of developing drugs from scratch, and acquisitions, the quicker but pricier route of buying into existing biotechs with promising pipelines. Which is the smarter bet? The answer, like most things in life, is that it depends.</p>
<p>Deloitte found that the average cost of developing a new drug among the top 20 global biopharmas it studied rose 15% ($298 million) last year to approximately $2.3 billion. That figure includes the average cost of developing a candidate from discovery through clinical trials to the market.</p>
<p><a href="https://richardameyer.medium.com/buying-vs-r-d-is-it-cheaper-to-acquire-existing-biotechs-or-invest-in-your-own-r-d-3440a0c6edec"><strong>Visit Now</strong></a></p>